NEW YORK (GenomeWeb) — OneOme announced today that its RightMed pharmacogenomic test has received approval from the New York State Department of Health (NYSDH).
RightMed covers 27 genes in which variants are known to contribute to the effectiveness or safety of more than 360 medications for 30 conditions. With the NYSDH approval, Minneapolis-based OneOme said it can offer the PCR-based test in all 50 states, in addition to certain international locations.
In October, OneOme — which was founded by the Mayo Clinic and venture firm Invensure — signed an agreement to offer RightMed through Croatia's Catherine Specialty Hospital. The company has also forged deals to offer the test in Hong Kong, Japan, and Macau in partnership with Rainbow Genomics; in Canada with ProZed Pharmacy Solutions; in Mexico with Total Quality Medicine; and in Australia with Genome.One.